SINOMED(SH:688108) Xin Lang Cai Jing·2025-09-30 03:41Core Viewpoint - Sino Medical's stock has shown significant volatility and growth, with a year-to-date increase of 190.88% as of September 30, 2023, despite recent fluctuations in trading volume and net capital flow [1][2]. Financial Performance - For the first half of 2025, Sino Medical reported revenue of 240 million yuan, representing a year-on-year growth of 12.53% [2]. - The net profit attributable to shareholders for the same period was 13.84 million yuan, showing a substantial increase of 296.54% year-on-year [2]. Stock Market Activity - As of September 30, 2023, Sino Medical's stock price was 28.39 yuan per share, with a market capitalization of 11.81 billion yuan [1]. - The stock experienced a trading volume of 341 million yuan, with a turnover rate of 2.95% [1]. - The company has appeared on the stock market's "龙虎榜" (Dragon and Tiger List) six times this year, with the most recent appearance on August 22 [1]. Shareholder Information - As of June 30, 2023, Sino Medical had 11,100 shareholders, an increase of 0.42% from the previous period [2]. - The average number of tradable shares per shareholder was 37,515, reflecting a slight increase of 0.21% [2]. Business Overview - Sino Medical, established on September 21, 2007, specializes in the research, production, and sales of high-end interventional medical devices, focusing on cardiovascular, cerebrovascular, and structural heart disease treatments [1]. - The revenue composition of the company includes stents (59.76%), balloons (32.68%), and other products (7.56%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and consumables sector [1].